<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032382</url>
  </required_header>
  <id_info>
    <org_study_id>PG-PERU-08-03, A-15809</org_study_id>
    <nct_id>NCT01032382</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)</brief_title>
  <official_title>Double-blind, Randomized, Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in Peru</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy
      of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in
      subjects with cutaneous leishmaniasis (CL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-site, randomized, double-blind, two group trial assessing the PK,
      safety and efficacy of WR 279,396 Topical Cream and Paromomycin Topical Cream in subjects
      with CL. Subjects will be screened over a period up to 28 days for eligibility including
      parasitology for confirmation of ulcerative CL. Subjects will be randomized in a targeted 1:1
      ratio to receive either WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) (target
      n=15) or Paromomycin Topical Cream (15% paromomycin topical cream) (target n=15) by topical
      application to CL lesions once daily for 20 days. Because the primary objective of this trial
      is to determine PK in all age groups, subjects will be stratified by age: 5-11 yrs, 12-17
      yrs, and ≥ 18 yrs with at least 6 PK subjects in each age stratum and no more than 18 total
      subjects will be randomized in any age range. A target of 30 subjects who complete the PK
      part of the study is the goal. Any subject who does not complete the PK portion of the study
      will be replaced with another subject from the same age group that will be given the same
      treatment assignment to maintain the balance. Safety will be assessed by monitoring adverse
      events (AEs), lesion site reactions, vital signs, and blood creatinine levels. The primary
      efficacy analysis will be by evaluation of an index lesion with secondary efficacy analyses
      including all lesions. Lesions will also be examined for parasite negativity by classical
      means (positive culture for promastigotes or microscopic identification of amastigotes in
      stained lesion tissue) on Day 21.

      In adult subjects, on Days 1 and 20, blood will be collected prior to topical cream
      application and at 0.5h, 1h, 2h, 3h, and 4h ± 5 minutes and 8h, 12h, and 24h ± 15 minutes
      after completion of cream application to determine plasma levels of paromomycin and
      gentamicin to calculate PK parameters. Thus, the last blood draw in this series will occur on
      Day 21. In addition, blood will be collected on Days 4, 7, 12, and 17 ± 1 day before study
      drug application to examine trough plasma levels of paromomycin and gentamicin. A follow-up
      plasma sample for PK analysis will also be obtained on Day 28 ± 2 days.

      Subjects under the age of 18 years will have a total of four blood samples drawn. The first
      will be drawn at pre-application and the second will be drawn at 4 hours ± 5 minutes after
      completion of application of the topical cream on Study Day 1. The third will be drawn
      pre-application and the fourth at 4 hours ± 5 minutes after completion of application of the
      topical cream on Study Day 20. Subjects who receive Paromomycin Topical Cream are not
      expected to have blood levels of gentamicin, but as the study is blinded, plasma specimens
      will be tested for both paromomycin and gentamicin.

      The index lesion (primary ulcerated) and all other ulcerated lesions will be assessed for
      clinical response by measurement of the length and width of area of ulceration. A lesion will
      be considered to be completely cured if 100% re-epithelialization is observed (i.e., this is
      a measurement of ulceration of 0 x 0 mm). Non-ulcerated lesions will also be measured to
      monitor the total area of exposure of lesions to study drug and will be evaluated for cure
      (i.e., absence of signs of an active lesion).

      Subjects will have an in-clinic follow-up weekly (Days 28, 35, 42, 49, 56, and 63 ± 2 days)
      after completion of treatment for safety assessments, lesion measurements, and lesion
      photographs. On Day 21, index lesions in adult subjects that have not completely
      re-epithelialized will be assessed for parasites by classical means (positive culture for
      promastigotes or microscopic identification of amastigotes in stained lesion tissue). An
      interim analysis of all of the data collected on all subjects who were randomized and
      completed the nominal Day 63 follow-up will be performed to make decisions about the final
      design of a Phase 3 trial. Subjects will continue to be followed for outcomes at Day 100 and
      168 ± 14 days. A final analysis of outcomes after the longer term followup period has been
      completed for all subjects will be performed when the trial is closed. Follow-up evaluations
      include AEs, medication use, lesion measurements, and lesion photographs.

      Patients who fail therapy (see definition of failure below) may be administered rescue
      therapy at the discretion of the patient's personal physician.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Final Clinical Cure for Index Lesions</measure>
    <time_frame>Initial clinical cure by day 63 and no relapse by day 168</time_frame>
    <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63 followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion by Day 168. Relapse was defined as an index lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or an index lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detectable Paromomycin Plasma Levels</measure>
    <time_frame>Day 4, 7, 12, 17, 20, 28</time_frame>
    <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paromomycin Plasma Concentrations in Children</measure>
    <time_frame>0 and 4 hours on days 1 and 20</time_frame>
    <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Tmax</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Pharmacokinetic Parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Area Under the Curve (AUC)</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: t(1/2)</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: Cmax/D</measure>
    <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
    <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameter: AUC/D</measure>
    <time_frame>Days 1 and 20</time_frame>
    <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Clinical Cure on All Lesions Independent of Subjects</measure>
    <time_frame>Initial clinical cure by day 63 and no relapse by day 168</time_frame>
    <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of lesion by nominal Day 63 followed by 100% re-epithelialization of the lesion on or before nominal Day 100; AND,
Subject has no relapse of lesion by Day 168. Relapse was defined as a lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or a lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Index Lesions Meeting Criteria for Clinical Cure During the Study</measure>
    <time_frame>Day 1, 4, 7, 12, 17, 20, 28, 35, 42, 49, 56, 63, 100, 168</time_frame>
    <description>Number of study participants who meet the criteria for clinical cure (100% re-epithelialization) at specified timepoints during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Leishmaniasis, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Paromomycin Alone Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>WR 279,396</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)</intervention_name>
    <description>topical application to CL lesions once daily for 20 days</description>
    <arm_group_label>WR 279,396</arm_group_label>
    <other_name>Topical paromomycin/gentimicin cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paromomycin Alone Cream (15% paromomycin topical cream)</intervention_name>
    <description>topical application to CL lesions once daily for 20 days</description>
    <arm_group_label>Paromomycin Alone Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible for the study, the following must be answered &quot;YES&quot; or not applicable,
             as appropriate for the study subject:

               1. Is the subject a male or female at least 5 years-of-age?

               2. Is the subject or legal guardian able to give written informed consent or assent,
                  as appropriate?

               3. Does the subject have a diagnosis of CL in at least one lesion by at least one of
                  the following methods: 1) positive culture for promastigotes, or 2) microscopic
                  identification of amastigotes in stained lesion tissue.

               4. Does the subject have at least one ulcerative lesion ≥ 1 cm and ≤ 5 cm, that
                  meets the criteria for an index lesion?

               5. Is the subject willing to forego other forms of treatments for CL including other
                  investigational treatments during the study?

               6. In the opinion of the investigator, is the subject (or their legal guardian)
                  capable of understanding and complying with the protocol?

               7. If female and of child-bearing potential, did the subject have a negative
                  pregnancy test during screening and agree to use an acceptable method of birth
                  control during the treatment phase and for 1 month after treatment is completed?

               8. Does the subject have adequate venous access for blood draws?

        Exclusion Criteria:

        To be eligible for the study, the following must be answered &quot;NO&quot; or not applicable as
        appropriate for the study subject:

          1. Does the subject have only a single lesion whose characteristics include any of the
             following: verrucous or nodular lesion (non-ulcerative), lesion &lt;1 cm in its greatest
             diameter, lesion in a location that in the opinion of the Investigator is difficult to
             maintain application of study drugs topically?

          2. Does the subject have a lesion due to leishmania that involves the mucosa or palate or
             any signs of mucosal disease that might be due to leishmania?

          3. Does the subject have signs and symptoms of disseminated disease in the opinion of the
             Principal Investigator?

          4. Does the subject have &gt; 10 lesions?

          5. Is the subject a female who is breast-feeding?

          6. Does the subject have an active malignancy or history of solid, metastatic or
             hematologic malignancy with the exception of basal or squamous cell carcinoma of the
             skin that has been removed?

          7. Does the subject have significant organ abnormality, chronic disease such as diabetes,
             severe hearing loss, evidence of renal or hepatic dysfunction, or creatinine greater
             than 15%, or aspartate aminotransferase (AST), or alanine aminotransferase (ALT)
             greater than 1.5 times the above the upper limit of normal (ULN) as defined by the
             clinical laboratory defined normal ranges?

          8. Has the subject received treatment for leishmaniasis including any medication with
             pentavalent antimony including sodium stibogluconate (Pentostam), meglumine
             antimoniate (Glucantime); amphotericin B (including liposomal amphotericin B and
             amphotericin B deoxycholate); or other medications containing paromomycin
             (administered parenterally or topically) or methylbenzethonium chloride (MBCL);
             gentamicin; fluconazole; ketoconazole; pentamidine; miltefosine, azithromycin or
             allopurinol that was completed within 8 weeks of starting study treatments?

          9. Does the subject have a history of known or suspected hypersensitivity or
             idiosyncratic reactions to aminoglycosides?

         10. Does the subject have any other topical disease/condition which would interfere with
             the objectives of this study?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Llanos-Cuentas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Peruana Cayetano Heredia (UPCH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Peruana Cayetano Heredia (UPCH)</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <results_first_submitted>June 6, 2014</results_first_submitted>
  <results_first_submitted_qc>August 6, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leishmaniasis</keyword>
  <keyword>cutaneous</keyword>
  <keyword>WR 279,396</keyword>
  <keyword>paromomycin</keyword>
  <keyword>gentamicin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Cutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Paromomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
        <group group_id="P2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease dissemination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Index lesion relapse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
        <group group_id="B2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.7" spread="16.2"/>
                    <measurement group_id="B2" value="18.2" spread="15.1"/>
                    <measurement group_id="B3" value="19.5" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adults (18+ years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children (12 to 17 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children (5 to 11 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Final Clinical Cure for Index Lesions</title>
        <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63 followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion by Day 168. Relapse was defined as an index lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or an index lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
        <time_frame>Initial clinical cure by day 63 and no relapse by day 168</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Final Clinical Cure for Index Lesions</title>
          <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of index lesion by nominal Day 63 followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,
Subject has no relapse of index lesion by Day 168. Relapse was defined as an index lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or an index lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Detectable Paromomycin Plasma Levels</title>
        <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
        <time_frame>Day 4, 7, 12, 17, 20, 28</time_frame>
        <population>Adults (18+ years)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Detectable Paromomycin Plasma Levels</title>
          <description>Paromomycin plasma concentrations following administration of paromomycin alone or WR 279,396 in adults</description>
          <population>Adults (18+ years)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="27.0"/>
                    <measurement group_id="O2" value="37.3" spread="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="23.1"/>
                    <measurement group_id="O2" value="17.9" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="33.2"/>
                    <measurement group_id="O2" value="78.9" spread="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.0" spread="327.0"/>
                    <measurement group_id="O2" value="162.0" spread="123.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" spread="109.0"/>
                    <measurement group_id="O2" value="128.0" spread="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paromomycin Plasma Concentrations in Children</title>
        <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
        <time_frame>0 and 4 hours on days 1 and 20</time_frame>
        <population>Children ages 5 to 17 (inclusive)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Paromomycin Plasma Concentrations in Children</title>
          <description>Paromomycin plasma concentrations 4 hours following administration of paromomycin alone or WR 279,396 in children</description>
          <population>Children ages 5 to 17 (inclusive)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="20.5"/>
                    <measurement group_id="O2" value="22.1" spread="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" spread="88.0"/>
                    <measurement group_id="O2" value="322.0" spread="757.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" spread="59.9"/>
                    <measurement group_id="O2" value="89.2" spread="132.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20 hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="744.0" spread="503.0"/>
                    <measurement group_id="O2" value="1030.0" spread="1460.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Cmax</title>
        <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults (18+ years)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Cmax</title>
          <description>Cmax of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults (18+ years)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="511" spread="445"/>
                    <measurement group_id="O2" value="155.0" spread="139.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1400" spread="842"/>
                    <measurement group_id="O2" value="882" spread="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Tmax</title>
        <description>Pharmacokinetic Parameter: Tmax</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults (18+ years). On day 1, Paromomycin Alone Treatment group N = 4; WR 279,396 group N = 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Tmax</title>
          <description>Pharmacokinetic Parameter: Tmax</description>
          <population>Adults (18+ years). On day 1, Paromomycin Alone Treatment group N = 4; WR 279,396 group N = 3.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.5"/>
                    <measurement group_id="O2" value="3" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="3.13"/>
                    <measurement group_id="O2" value="3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Area Under the Curve (AUC)</title>
        <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults (18+ years)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Area Under the Curve (AUC)</title>
          <description>Area under the curve (AUC) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults (18+ years)</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3154" spread="3562"/>
                    <measurement group_id="O2" value="1228" spread="1413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13331" spread="9156"/>
                    <measurement group_id="O2" value="8955" spread="1955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: t(1/2)</title>
        <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults (18+ years). WR 279,396 group measurements Day 1 N = 2 and Day 20 N = 4. One study participant in the Paromomycin Alone Treatment was withdrawn at Day 100.</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: t(1/2)</title>
          <description>t(1/2) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults (18+ years). WR 279,396 group measurements Day 1 N = 2 and Day 20 N = 4. One study participant in the Paromomycin Alone Treatment was withdrawn at Day 100.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.23"/>
                    <measurement group_id="O2" value="4.51" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="3.29"/>
                    <measurement group_id="O2" value="6.81" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: Cmax/D</title>
        <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>0, 0.5, 1.0, 2.0, 3.0, 4.0, 8.0, 12.0, 24.0 hours on both Days 1 and 20</time_frame>
        <population>Adults (18+ years)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: Cmax/D</title>
          <description>Maximum observed plasma concentration divide by topical dose (Cmax/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults (18+ years)</population>
          <units>1/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185" spread="144"/>
                    <measurement group_id="O2" value="45.9" spread="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368" spread="196"/>
                    <measurement group_id="O2" value="283" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Parameter: AUC/D</title>
        <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
        <time_frame>Days 1 and 20</time_frame>
        <population>Adults (18+ years)</population>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameter: AUC/D</title>
          <description>Area under the plasma concentration-time curve over 24 hrs divided by topical dose (AUC/D) of paromomycin following administration of paromomycin alone or WR 279,396 to adults in Panama</description>
          <population>Adults (18+ years)</population>
          <units>hr/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="996.7" spread="976.1"/>
                    <measurement group_id="O2" value="340.5" spread="368.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3335" spread="1482"/>
                    <measurement group_id="O2" value="3155" spread="2151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Clinical Cure on All Lesions Independent of Subjects</title>
        <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of lesion by nominal Day 63 followed by 100% re-epithelialization of the lesion on or before nominal Day 100; AND,
Subject has no relapse of lesion by Day 168. Relapse was defined as a lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or a lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
        <time_frame>Initial clinical cure by day 63 and no relapse by day 168</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Final Clinical Cure on All Lesions Independent of Subjects</title>
          <description>Final clinical cure was defined as follows:
Subject has initial clinical cure (100% re-epithelialization of lesion by nominal Day 63); OR,
Subject has initial clinical improvement (&gt; 50% re-epithelialization of lesion by nominal Day 63 followed by 100% re-epithelialization of the lesion on or before nominal Day 100; AND,
Subject has no relapse of lesion by Day 168. Relapse was defined as a lesion meeting the criteria for initial clinical cure that had any new ulceration/nodule (&gt; 0 x 0 mm measurement) by nominal day 168, or a lesion meeting the criteria for initial clinical improvement that subsequently enlarged by nominal Day 168.</description>
          <units>Cured ulcerated lesions</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of ulerated lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Index Lesions Meeting Criteria for Clinical Cure During the Study</title>
        <description>Number of study participants who meet the criteria for clinical cure (100% re-epithelialization) at specified timepoints during the study.</description>
        <time_frame>Day 1, 4, 7, 12, 17, 20, 28, 35, 42, 49, 56, 63, 100, 168</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paromomycin Alone Treatment</title>
            <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
          <group group_id="O2">
            <title>WR 279,396</title>
            <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Index Lesions Meeting Criteria for Clinical Cure During the Study</title>
          <description>Number of study participants who meet the criteria for clinical cure (100% re-epithelialization) at specified timepoints during the study.</description>
          <units>Lesions meeting clinical cure criteria</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 49</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 168</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paromomycin Alone Treatment</title>
          <description>Paromomycin Alone Cream (15% paromomycin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
        <group group_id="E2">
          <title>WR 279,396</title>
          <description>WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to CL lesions once daily for 20 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding anovulatory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Application site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cutaneous leishmaniasis relapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Superinfection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cutaneous leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Parties agree to keep Referenced Information in strict confidence and not to disclose it to any other party or use Referenced Information for any purpose, other than for the performance of the clinical studies herein described, without prior written consent of the providing party. Parties may disclose the Referenced Information to their employees and consultants, and employees and consultants of their affiliates, who have a need to know such Referenced Information.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All randomized subjects were included in the mITT analysis. All subjects also met the criteria for the evaluable subset; therefore, no separate analysis of an evaluable subset of subjects was performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director, Division of Regulated Activites and Compliance</name_or_title>
      <organization>US Army Medical Materiel Development Activity (USAMMDA)</organization>
      <phone>301-619-0197</phone>
      <email>usarmy.detrick.medcom-usammda.mbx.usamrmc-regulatory-affairs@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

